IgM-enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis

Sponsor
Goethe University (Other)
Overall Status
Completed
CT.gov ID
NCT02444871
Collaborator
(none)
30
1
5.9
5

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the effect of IgM-enriched immunoglobulins (Pentaglobin) on the endotoxin activity, conventional coagulation parameters, viscoelastic and aggregometric measurements of patients with severe sepsis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Before the change of the standard operating procedure (SOP) with the implementation of the application of IgM-enriched immunoglobulins to patients with severe sepsis and septic shock conventional inflammatory and coagulation parameters, viscoelastic and aggregometric measurements as well as the endotoxin activity was measured in 15 patients. After the change of SOP the same parameters were recorded for additional 15 patients.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    30 participants
    Time Perspective:
    Prospective
    Official Title:
    Immunoglobulin-M-enriched (IgM-enriched) Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis
    Study Start Date :
    Jan 1, 2013
    Actual Primary Completion Date :
    Jul 1, 2013
    Actual Study Completion Date :
    Jul 1, 2013

    Outcome Measures

    Primary Outcome Measures

    1. Change in endotoxin activity [Baseline, 6, 12, 24, 30, 36, 48, 54, 60, 72, 78 and 84 hours]

      The endotoxin activity of the patients was measured with a point of care assay and noted in on an arbitrary scale from 0 to 1.0

    Secondary Outcome Measures

    1. Changes in CT-NATEM [Baseline, 6, 12, 24, 30, 36, 48, 54, 60, 72, 78 and 84 hours]

      Changes in clotting time (CT) of the naturally activated rotational thrombelastometry (ROTEM), results were noted in seconds.

    2. Changes in MCF-NATEM [Baseline, 6, 12, 24, 30, 36, 48, 54, 60, 72, 78 and 84 hours]

      Changes in maximum clot firmness (MCF) of the naturally activated rotational thrombelastometry (ROTEM), results were noted in millimeters.

    3. Changes in CFT-NATEM [Baseline, 6, 12, 24, 30, 36, 48, 54, 60, 72, 78 and 84 hours]

      Changes in clot formation time (CFT) of the naturally activated rotational thrombelastometry (ROTEM), results were noted in seconds.

    4. Changes in NATEM-Alpha angle [Baseline, 6, 12, 24, 30, 36, 48, 54, 60, 72, 78 and 84 hours]

      Changes in Alpha angle of the naturally activated rotational thrombelastometry (ROTEM), results were noted in °.

    5. Changes in ADPtest [Baseline, 6, 12, 24, 30, 36, 48, 54, 60, 72, 78 and 84 hours]

      Platelet activation was measured as the area under the curve of a multiple electrode aggregometry. Platelets were activated using adenosine diphosphate (ADPtest)

    6. Changes in ASPItest [Baseline, 6, 12, 24, 30, 36, 48, 54, 60, 72, 78 and 84 hours]

      Platelet activation was measured as the area under the curve of a multiple electrode aggregometry. Platelets were activated using arachidonic acid (ASPItest)

    7. Changes in TRAPtest [Baseline, 6, 12, 24, 30, 36, 48, 54, 60, 72, 78 and 84 hours]

      Platelet activation was measured as the area under the curve of a multiple electrode aggregometry. Platelets were activated using thrombin receptor activating peptide (TRAPtest)

    8. Platelet count [Baseline, 12, 24, 36, 48, 60, 72 and 84 hours]

      Platelet count was determined in the clinical routine and noted /nl.

    9. Interleukin-6 [Baseline, 12, 24, 36, 48, 60, 72 and 84 hours]

      Interleukin-6 level was determined in the clinical routine and was noted in pg/ml.

    10. Leukocyte count [Baseline, 12, 24, 36, 48, 60, 72 and 84 hours]

      Leukocyte count was determined in the clinical routine and was noted /µl.

    11. Lipopolysaccharide-binding-protein (LBP) [Baseline, 24, 48 and 72 hours]

      Lipopolysaccharide-binding-protein (LBP) was determined in the clinical routine and was noted in µg/l.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • age >18 years

    • proven or suspected severe sepsis or septic shock

    • written consent of the patient or a legal person in charge

    Exclusion Criteria:
    • Pregnancy

    • anticoagulation other than heparin

    • Inherited coagulopathy or thrombophilia

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Johann Wolfgang Goethe-University Frankfurt Hessen Germany 60590

    Sponsors and Collaborators

    • Goethe University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Saskia Wand, Dr. Saskia Wand, Goethe University
    ClinicalTrials.gov Identifier:
    NCT02444871
    Other Study ID Numbers:
    • DEEP Trial
    First Posted:
    May 15, 2015
    Last Update Posted:
    May 28, 2015
    Last Verified:
    May 1, 2015
    Keywords provided by Saskia Wand, Dr. Saskia Wand, Goethe University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 28, 2015